MARCO and chronic obstructive pulmonary disease: Their findings support the use of pharmaceutical medicines like sulforaphane to target this pathway and prevent COPD exacerbations caused by bacterial infection by highlighting the significance of Nrf2 and its downstream target MARCO in enhancing antibacterial defences.